Publication date: 22/09/2017
Camel-IDS, a privately held clinical stage radionuclide therapy company in oncology, today announces the appointment of Ruth Devenyns as Chief Executive Officer and director.
Most recently, Ruth was CFO of Ogeda, a biotech company acquired by Astellas in May 2017 in a EUR 800m transaction. Before joining Ogeda, Ruth worked for more than 20 years in the financial industry, both in healthcare investment banking (KBC Securities and Bank Degroof Petercam) as well as in healthcare venture capital (KBC and Korys). She was a director of the regional biotech industry association flanders.bio (2008-2016) and is currently an independent director of Euronext-listed MDxHealth.
Tony Lahoutte, MD, PhD, co-founder and CMO of Camel-IDS, commented:
“We are delighted that Ruth is joining Camel-IDS. With her background and experience, she will help us transition from science to business.” Ruth Devenyns, Chief Executive Officer of Camel-IDS, commented: “Camel-IDS is an exciting young company in the emerging field of radionuclide therapy. The company has demonstrated creativity, dedication and efficiency to be in the clinic in less than three years after its incorporation. I look forward to working closely with the team to lead the company in its further development”.
Camel-IDS, incorporated in 2014 as a spin-off company of Vrije Universiteit Brussel (VUB), develops new targeted cancer drugs, using camelid single domain antibodies (sdAb) labeled with radioisotopes. The company’s lead product CAM-H2, a new treatment option in HER2-positive cancers, is currently in Phase I clinical trials. The pipeline further consists of two pre-clinical programs leveraging on the technology strengths. Camel-IDS has received seed funding from the Fournier-Majoie Foundation and three business angels, complemented with non-dilutive funding from Innoviris. For more information, please visit www.camel-ids.com.